Table 2

Cumulative probability of ever medical use within the first, fifth and ninth years of diagnosis in patients with Crohn's disease diagnosed in Cohorts III and IV

	Cohort III (1995–2002) n=3718		Cohort IV (2003–2011) n=5552		Homogeneity test for rates within <1,1–4, 5–8 years*
	Users	Cumulative probability (%)	Users	Cumulative probability (%)	Homogeneity test for rates within <1,1–4, 5–8 years*
Use† within first year of diagnosis					p_<1 year
5-ASA‡	1866	51	1021	19	<0.001
Topical corticosteroids	618	17	987	19	0.02
Oral corticosteroids	1335	37	1855	35	0.29
Azathioprine	547	15	1323	25	<0.001
TNF-α blockers§	1	0.1	456	9	<0.001
Use within first 5 years of diagnosis					p_{1–4 years}
5-ASA‡	2024	56	1151	23	<0.001
Topical corticosteroids	953	27	1225	26	<0.001
Oral corticosteroids	1774	49	2212	46	0.006
Azathioprine	986	28	1681	36	0.18
TNF-α blockers§	46	3	783	19	<0.001
Use within first 9 years of diagnosis					p_{5–8 years}
5-ASA‡	2057	56	1164	24	0.43
Topical corticosteroids	1071	31	1264	30	0.82
Oral corticosteroids	1996	56	2280	53	0.45
Azathioprine	1126	32	1719	39	0.70
TNF-α blockers§	164	10	839	23	0.35

*p Value for homogeneity performed by log rank test, p value compares rates within first year of diagnosis (p<_1 year) from 1–4 years (p_{1–4 years}) and 5–8 years of diagnosis (p_{5–8 years}).
†Use defined as ever use of the drug in question.
‡5-aminosalicylates/sulfasalazine.
§Users of TNF-α blockers in Cohort III contains only patients diagnosed after 1998 (n=2381).